Prime Medicine grants director 75,000 stock options

Prime Medicine director David P. Schenkein received a grant of stock options for 75,000 shares of common stock.

Rhea-AI Filing Summary

Prime Medicine director David P. Schenkein received a grant of stock options for 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036. Following this grant, he holds options on 75,000 shares.

The options will vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual meeting of stockholders, provided he remains in continuous service with the company through that vesting date. This is a compensation-related, non‑market transaction.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Schenkein David P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	75,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 75,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Key Figures

Options granted: 75,000 options Exercise price: $3.06 per share Expiration date: June 5, 2036 +2 more

5 metrics

Options granted 75,000 options Stock Option (right to buy) granted to director

Exercise price $3.06 per share Conversion or exercise price of granted options

Expiration date June 5, 2036 Option expiration for the 75,000-share grant

Total options after grant 75,000 options Total derivative holdings following this transaction

Vesting date outer limit June 5, 2027 Latest date when options vest in full, subject to service

Key Terms

Stock Option (right to buy), exercise price, vest in full, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 3.0600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares subject to this option shall vest in full upon the earlier"

annual meeting of stockholders financial

"or (ii) the date of the next annual meeting of stockholders"

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prime Medicine (PRME) report in this Form 4 filing?

Prime Medicine reported a compensation-related stock option grant to director David P. Schenkein. He received options on 75,000 shares of common stock, with specific vesting terms, an exercise price, and an expiration date disclosed in the filing.

How many stock options did David P. Schenkein receive from Prime Medicine (PRME)?

David P. Schenkein received stock options for 75,000 shares of Prime Medicine common stock. These options represent the entire derivative position reported in this filing and are shown as his total options following the transaction.

What are the vesting terms of the Prime Medicine (PRME) stock options granted?

The options vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual meeting of stockholders. Vesting is conditioned on David P. Schenkein’s continuous service to the company through the applicable vesting date.

What is the exercise price and expiration date of the Prime Medicine (PRME) options?

The granted stock options carry an exercise price of $3.06 per share and expire on June 5, 2036. These terms define the cost to purchase shares and the final date by which the options must be exercised.

Is the Prime Medicine (PRME) Form 4 transaction an open-market trade?

No. The Form 4 describes a grant or award of stock options as compensation, not an open-market purchase or sale. It is recorded with transaction code “A,” indicating a grant, award, or other acquisition from the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schenkein David P

(Last) (First) (Middle)

C/O PRIME MEDICINE, INC.

60 FIRST STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prime Medicine, Inc. [ PRME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.06	06/05/2026		A		75,000		(1)	06/05/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Remarks:

	/s/ Ryan Brown, attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)